Boston Heart Lab (Framingham, MA) a commercial-stage diagnostics company focused on lipid-based testing for cardiovascular disease management, closed a $10M Series C financing. Participants include Bain Capital Ventures.

Lineagen (Salt Lake City, UT) a development stage content-based biomarker discovery company focused on diagnostic tests for autism, multiple sclerosis and COPD, closed a $5M Series A, bringing the total round to $10.8M. Participants include PrairieGold Venture Partners, vSpring Capital, Sanderling Ventures and Mesa Verde Venture Partners.

Metamark Genetics (Cambridge, MA) a development-stage molecular diagnostics company focused on prognostic assays for early-stage cancers, closed a $22M Series B financing. Participants may have included Perseus.

Molecular Detection (Wayne, PA) a commercial-stage molecular diagnostics company focused on MRSA detection, closed a $1.4M Series C financing, bringing the total round to $4.7M. Participants include MentorTech Ventures.

SynapDx (Waltham, MA) a development-stage diagnostic company focused on the early detection of autism, closed a $9M Series A financing. Participants include Bain Capital Ventures, General Catalyst Partners and North Bridge Venture Partners.

BioScale (Cambridge, MA) a commercial-stage therapeutic and diagnostics protein biomarker analytics device company, closed a $25M Series D financing. Participants include Morningside Venture, New Science Ventures, WFD Ventures and F2 Ventures.

Delphinus Medical Technologies (Detroit, MI) a development-stage medical device company focused on tomographic ultrasound imaging for breast cancer, closed an $8M Series A financing. Participants include Arboretum Ventures, Beringea and North Coast Technology Investors.

Predictive Biosciences (Lexington, MA) a commercial-stage molecular diagnostic company focused on oncology assays, closed a $25M Series C financing. Participants ProQuest Investments, Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Veracyte (San Francisco, CA) a clinical-stage molecular diagnostics company focused on non-small cell lung cancer and thyroid cancers, closed a $28M Series B financing. Participants include Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech and Versant Ventures.

T2 Biosystems (Cambridge, MA) a development-stage molecular and immunodiagnostic company focused on a nanotechnology and miniaturized magnetic resonance designed to optimize sample prep, closed a $12M Series C financing. Participants include Physic Ventures, Arcus Ventures, RA Capital, Camros Capital, WS Investments, Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners and Partners Healthcare.

Rheonix (Ithaca, NY) a development-stage molecular diagnostic company focused on immunoassays, pathogen identification gene sequence detection and cell-based assays, closed a $12.6M Series A financing. Participants include Cayuga Venture Fund.

Astute Medical (San Diego, CA) a development-stage diagnostic company focused on the identification and validation of protein biomarkers that can test for hospital acquired acute conditions like sepsis, kidney injury and abdominal pain, closed a $26.5M Series B financing. Participants include Domain Associates, Delphi Ventures, Johnson & Johnson Development Corp. and De Novo Ventures.

Oxford Immunotec (United Kingdom) a commercial-stage molecular diagnostic company focused on an vitro test for the diagnosis of active and latent tuberculosis infection, closed a $26M Series D financing. Participants include New Leaf Venture Partners, Kaiser Permanente Ventures, Clarus Ventures, Wellington Partners, National Technology Enterprises Company, Spark Ventures, DFJ Esprit, Oxford University and Dow Chemical.